中文

AI FOR SCIENCE · ON THE RECORD

Insilico Medicine

Drug discoveryHong Kong and Cambridge, MassachusettsFounded 2014Website ↗

Generative-AI drug discovery (target finding, molecule generation) with its own clinical pipeline led by a fibrosis drug, plus licensing deals with Lilly, Exelixis and others.

Full funding record →On the timeline →People filter →

Research on the record

Graded by how far the evidence went, not how good the result is. See the methodology.

Read on AI4S.fyi

Also on the timeline

People

Only people the AI4S.fyi record has named: in a round, a timeline entry, commentary, an interview or a sourced role. Not the full team.

Named on AI4S.fyi

Named backers

Funding rounds tracked

Disclosed funding$497M
Latest roundabout HK$2.026B netIPO · confirmed · 2025-12-30
  • 2025-12-30IPO · about HK$2.026B netconfirmedAnchored by Lilly, Tencent, Temasek, Oaktree, Schroders, UBS, ChinaAMC, China Pacific Insurance (CPIC), Fullgoal Fund Management, Harvest Fund Management, Taikang Life, E Fund Management, RTW, Exome, InfiniStated use: late-stage clinical programmes, new generative AI models, automated labs and early discovery
  • 2025-03-13Series E · $110MconfirmedLed by Value Partners Group private equity fundStated use: AI models, automated lab, clinical validation of the lead IPF drug
  • 2022-08-10Series D (second close) · $35MconfirmedLed by Prosperity7 (Aramco)Stated use: accelerate internal programmes and use its AI platform to find more new therapeutics
  • 2022-06-06Series D · $60MconfirmedWith BHR Partners, Warburg Pincus, B Capital Group, Qiming Venture Partners, BOLD Capital Partners, Pavilion Capital, Alex ZhavoronkovStated use: pipeline, Pharma.AI, robotic drug-discovery lab
  • 2021-06-22Series C · $255MconfirmedLed by Warburg Pincus · With Qiming Venture Partners, Lilly Asia Ventures, OrbiMed, Deerfield Management, Sequoia Capital China, B Capital Group, Pavilion Capital, Eight Roads Ventures, Sinovation Ventures, BOLD Capital Partners, Formic Ventures, Baidu Ventures, CPE, Mirae Asset Capital, Maison Capital, Lake Bleu Capital, President International Development Corporation, Sage PartnersStated use: take programs into human trials; start new programs
  • 2019-09-10Series B · $37MconfirmedLed by Qiming Venture Partners · With Eight Roads Ventures, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu Ventures, Pavilion Capital, BOLD Capital PartnersStated use: commercialise its generative chemistry and target identification technology, build a senior team with pharma experience, and develop its pipeline in cancer, fibrosis, NASH, immunology and CNS for partnering

Each round links to its line on the funding record, with its source.

Also in Drug discovery on the funding board

The other companies the funding board files under the same field, latest round first. A list of what the record tracks, not a ranking or a market map.

  • 2026-10-29ALLOXSeed · US$10.5M (€9.4M)Measures the effects of thousands of protein mutations at once to map allosteric and other regulatory sites, and builds AI models on that data to find drug-binding spots on hard targets such as protein-protein interactions and transcription factors, for its own small molecules.
  • 2026-10-27Atlas BioSeed · $10MRuns in silico clinical trials, starting in immunology: a foundation model trained on about 2 million RNA readouts from human tissue predicts each virtual patient's response to several treatments and diseases, to help drug developers choose what to take into Phase II.
  • 2026-10-23Pathos AISeries E · $237MLicenses clinical-stage drugs from other companies and develops them itself, using an agent platform (Foundry, earlier PathOS) trained on patient records to choose assets, pick the patients most likely to respond and adjust trials as they run. Its pipeline is in cancer: prostate cancer, multiple myeloma, lung and breast cancer and TROP2/HER3-expressing solid tumours; in October 2026 it began work in Alzheimer's disease with Bristol Myers Squibb and Tempus.
  • 2026-10-23Zhichong PharmaSeries A1 · tens of millions of yuanDevelops new drugs for pets with generative AI, using its own small-molecule and large-molecule design engines (ChemoFetch and OmniFetch), and argues that testing in the target animal closes the loop from design to evidence faster than human drug development can; its programmes are in anti-infectives, chronic disease and ageing.
  • 2026-10-14Gaowei YiyaoPre-A · undisclosed; PEdaily says the company has raised several hundred million yuan so far this yearMines protein-interaction and other high-dimensional biology data with its own models to find drug targets others treat as undruggable, then runs its own small-molecule and antibody programmes. Its GROOVY platform found the target behind GW-01, a Notch-pathway inhibitor now in Phase I; ACUMEN maps pairs of neighbouring cell-surface proteins for bispecifics and NEXUS looks for tumour neoantigens.
  • 2026-10-14Iambic TherapeuticsIPO · $150MDesigns small-molecule cancer drugs with AI structure-prediction models (NeuralPLexer) linked to an automated chemistry and biology lab.

All 37 in this field →

This page compiles what AI4S.fyi has recorded and links each item to its source. It is not a grade of the organization and not its complete history: a blank means the record has not caught up as often as it means nothing happened.